Dr. Jon K. Hayashida Named Vice President Global Clinical and Medical Affairs for STAAR Surgical
"We are thrilled to welcome Jon to our team," said
Dr. Hayashida's professional career includes experience in corporate eye care, ophthalmic start-up companies and direct patient care. He held the position of Vice President of Clinical and Medical Affairs for Bausch and Lomb, Surgical, where he gained
About
STAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL." A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL." More than 500,000 Visian ICLs have been implanted to date. To learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 employees and markets lenses in over 60 countries. Headquartered in
Safe Harbor
All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: financial items; the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding potential new or improved products (including a presbyopic lens); and any statements of assumptions underlying any of the foregoing. Important additional factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company's Annual Report on Form 10-K for the year ended
These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: our limited capital resources and limited access to financing; the discretion of regulatory agencies to approve or reject new or improved products, or to require additional actions before approval (including but not limited to
CONTACT: Investors |
Media |
EVC Group |
EVC Group |
Brian Moore, 310-579-6199 |
Rob Swadosh, 212-850-6021 |
Doug Sherk, 415-652-9100 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-jon-k-hayashida-named-vice-president-global-clinical-and-medical-affairs-for-staar-surgical-300117580.html
SOURCE